CORDIS
EU research results

CORDIS

English EN
Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments - Sofia ref.: 116072

Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments - Sofia ref.: 116072

Objective

Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known that the subsequently altered interactions between neurons and glial cells contribute to pain development and to its chronification, the underlying mechanisms are poorly understood. Developing mechanism-based therapies targeting neuron-glial interactions to treat chronic pain will be crucial for improving the quality of life of many patients. Hence the development of novel therapeutic solutions represents a major challenge that demands a multi-disciplinary approach to decipher and understand pathological mechanisms and to translate them into predictive tools for drug development. The NGN-PET consortium addresses this challenge by forming a highly interdisciplinary team that builds upon expertise in areas of academic research on pain
mechanisms, industrial knowhow on human stem cell-based tool development, HTS technologies and drug discovery. To achieve its goal we will develop preclinical model systems and assays which recapitulate the human in vivo situation and which can be interrogated for the identification, validation of molecular targets and the development new treatments. A focus of the project will be chemotherapy induced NP and the interplay between nociceptors, microglia and Schwann cells. NGN-PET will carefully characterize rodent in vivo and in vitro models to identify these mechanisms, and will develop rat and human iPSCs based in vitro systems of neuron-glial co-cultures that can be interrogated for targets and used for compound identification and validation. NGN-PET will thus pose the basis for the translation of these model systems into high throughput screening platforms for pharmaceutical research and drug discovery.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

AXXAM SPA

Address

Via Meucci 3
20091 Bresso Milano

Italy

Activity type

Other

EU Contribution

€ 450 000

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

LIFE AND BRAIN GMBH

Germany

EU Contribution

€ 450 000

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 450 000

NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 150 000

ESTEVE PHARMACEUTICALS, SA

Spain

GRUENENTHAL GMBH

Germany

Project information

Grant agreement ID: 116072

Status

Ongoing project

  • Start date

    1 April 2017

  • End date

    31 March 2020

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 3 050 000

  • EU contribution

    € 1 500 000

Coordinated by:

AXXAM SPA

Italy